Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
WRF Capital
AddedFeb 15, 2024
UpdatedJun 28, 2026
WRF Capital

WRF Capital

Operating

Seattle-based WRF Capital transforms innovative ideas into successful businesses, focusing on life sciences and technology.

Location
Seattle, WA, US
Founded
1981
Firm
Compare
Portfolio
Employees
Website

Investments

Proniras
Proniras

Total Raised

$13.3M

Rounds

3

Series B$4.7MFebruary 2024
AdaptX
AdaptX

Total Raised

$20.9M

Rounds

5

Series B$10MSeptember 2023
Series A$6MJuly 2021
KayoThera
KayoThera

Total Raised

$13.9M

Rounds

4

Series A$5.2MJuly 2023
Wavely Diagnostics
Wavely Diagnostics
Seed

Total Raised

$5.6M

Rounds

7

Seed$1.4MJuly 2023
Pre-Seed$2.2MFebruary 2022
Somalytics
Somalytics

Total Raised

$1.9M

Rounds

1

Seed$1.9MAugust 2022
Birch.ai
Birch.ai

Total Raised

$3.9M

Rounds

3

Seed$3.1MJanuary 2022
Outpace Bio
Outpace Bio

Total Raised

$55M

Rounds

2

Series A$30MMarch 2021
ThruWave
ThruWave

Total Raised

$7.4M

Rounds

5

Seed$6.4MSeptember 2020
WiBotic
WiBotic

Total Raised

$8.2M

Rounds

2

Series A$5.7MJune 2020
Membrion
Membrion

Total Raised

$27.9M

Rounds

13

Series A$6MMarch 2020
Absci
Absci
Public

Total Raised

$237.9M

Rounds

11

Series D$10.4MJanuary 2020
Stasys
Stasys

Total Raised

$2.6M

Rounds

4

Series A$160kFebruary 2015
Mobisante
Mobisante
Acquired

Total Raised

$4.2M

Rounds

1

Series A$4.2MJune 2013
Modumetal
Modumetal

Total Raised

$101M

Rounds

13

Series Unknown$3.5MMay 2009
Globeimmune
Globeimmune
Acquired

Total Raised

$128.5M

Rounds

10

Series C$41.2MSeptember 2007
Omeros
Omeros
Public

Total Raised

$972M

Rounds

24

Series E$63MFebruary 2007
Vlst
Vlst
Public

Total Raised

$55M

Rounds

1

Series B$55MJune 2006
Accium BioSciences
Accium BioSciences

Total Raised

$3M

Rounds

1

Seed$3MJanuary 2006
Amnis
Amnis
Acquired

Total Raised

$21.9M

Rounds

4

Series Unknown$8.8MDecember 2001